
    
      This is a open label, multicenter, phase III study designed to evaluate the safety and
      efficacy in advanced esophageal squamous cell carcinoma and colorectal cancer treated with
      SCT-I10A combined SCT200 or SCT-I10A combined SCT200 plus chemotherapy.
    
  